logo

Integration of high resolution -OMICS datasets towards personalized therapy in bladder cancer

Location: Germany

Source: EU Funding & Tenders Portal

Project
Ended

"TheranOMICS Project aims at the recruitment of a highly-qualified research Associate to support the Innovation Business Idea of Mosaiques diagnostics GmbH (MOS). The Associate is expected to have expertise in statistics, computer science and biology. The objective is the integration of high resolution bladder cancer (BC) –omics datasets that are available at MOS to establish molecular profiles wh

Project Information FAQ

Project Information

3 Q
The project “Integration of high resolution -OMICS datasets towards personalized therapy in bladder cancer” is an infrastructure initiative, located in Germany. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

"TheranOMICS Project aims at the recruitment of a highly-qualified research Associate to support the Innovation Business Idea of Mosaiques diagnostics GmbH (MOS). The Associate is expected to have expertise in statistics, computer science and biology. The objective is the integration of high resolution bladder cancer (BC) –omics datasets that are available at MOS to establish molecular profiles which can predict disease outcome and treatment response. The tasks include application of state-of-the-art bioinformatics tools in the development of two predictive tools that together will be offered as a companion test to assist patient stratification and predict response in BC drug development. The first tool will be based on molecular features associated with the clinical status and will enable the stratification of BC patients to those with the higher probability to progress. The second tool will be built on molecules/biomarkers associated with drug response and will enable to prediction of success of chemotherapy, as a test case study. MOS Business Innovation Idea is the development of the above predictive tools, to be served as a ""business-to-business"" product for pharmaceutical companies developing Bladder Cancer (BC) drugs. The expected outcome is the improved stratification of BC patients and the increased efficacy of new therapeutic agents. The benefit for the customers (Pharmaceutical Industry) is the reduction of the number of investigated subjects, time requirement and cost of clinical trials. The benefit for MOS enterprise is the opening of new marketing possibilities and the positioning in the Market of Pharmaceutical Industry. As a secondary aim, we target implementation of the tools for BC Patient management, aiming at improved, personalized intervention to prolong patients’ lives and increase their quality of life. Thus, TheranOMICS aims beyond the one-year period of INNOSUP support and provides perspectives for the Associate for a long-term employment."

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data